1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide

• ChemBase ID: 72596
• Molecular Formular: C10H8F2N4O
• Molecular Mass: 238.1935264
• Monoisotopic Mass: 238.06661734
• SMILES: c1ccc(c(c1F)Cn1nnc(c1)C(=O)N)F
• Canonical SMILES: Fc1cccc(c1Cn1nnc(c1)C(=O)N)F
• InChI: InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
• InChIKey: POGQSBRIGCQNEG-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide
• IUPAC Traditional name: rufinamide
• Synonyms: 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; Rufinamide; Banzel; Rufinamide; 1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide-15N,d2; CGP 33101-15N,d2; E 2080-15N,d2; Inovelon; RUF 331-15N,d2; Rufinamide-15N,d2; 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide

Database IDs

• CAS Number: 106308-44-5
• MDL Number: MFCD00865314
• PubChem SID: 24724595; 162037521
• PubChem CID: 129228

CALCULATED PROPERTIES

• Acid pKa: 12.688372
• H Acceptors: 3
• H Donor: 1
• LogD (pH = 5.5): 1.2665975
• LogD (pH = 7.4): 1.2665997
• Log P: 1.2665976
• Molar Refractivity: 67.0702 cm^3
• Polarizability: 20.050259 Å^3
• Polar Surface Area: 73.8 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO; DMSO: soluble9 mg/mL; Methanol
• Apperance: white powder; White Solid
• Melting Point: 240-242°C
• Hydrophobicity(logP): 0.514

Safety Information

• Storage Condition: -20°C; -20°C Freezer, Under Inert Atmosphere; under inert gas
• German water hazard class: 3
• Storage Temperature: -20°C

Pharmacology Properties

• Target: Sodium channel

Product Information

• Purity: ≥98% (HPLC); 95%; 98%
• Salt Data: Free Base
• Empirical Formula (Hill Notation): C10H8F2N4O

DETAILS

Selleck Chemicals - S1256

Research Area: Lennox-Gastaut syndrome,Ep
Biological Activity:
Rufinamide, a triazole derivative, is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide is presumed to involve stabilization of the sodium channel inactive state, effectively keeping these ion channels closed. [1]

Sigma Aldrich - R8404

Biochem/physiol Actions
Broad-spectrum anticonvulsant.
Caution
Product is air sensitive
Diagnostic Implications
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Toronto Research Chemicals - R701552

Labelled Rufinamide (R701552). Antiepileptic triazole derivative which decreases firing by neurons at sodium channels. Anticonvulsant.

REFERENCES

• http://en.wikipedia.org/wiki/Rufinamide
• Cheung, W.K., et al.: Pharm. Res., 12, 1878 (1995)
• Cardot, J.-M., et al.: Biopharm. Drug Dispos., 19, 259 (1995)
• Palhagen, S., et al.: Epilepsy Res., 43, 115 (1995)